LQZ-7I

195822-23-2

348.35

DMSO : 125 mg/mL (358.83 mM; Need ultrasonic)

Apoptosis

LQZ-7I is a survivin-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors^[1]. IC50 & Target: Survivin^[1] In Vitro: LQZ-7I has improved cytotoxicity with IC₅₀s of 3.1 uM against C4-2 cells and 4.8 uM against PC-3 cells compared with the parent compound LQZ-7^[1].
LQZ-7I (10 uM; 0-6 hours) treatment reduces the expression of survivin. However, LQZ-7I does not reduce the expression of XIAP, CIAP1, and CIAP2. LQZ-7I may be selective to its intended target survivin^[1]. In Vivo: LQZ-7I (100 mg/kg; oral gavage every other day for a total of ten treatments) significantly suppresses tumor growth without any notable adverse effect on the mice^[1].